Navigation Links
Alnylam Reports Results of Human Experimental Infection Model with,Respiratory Syncytial Virus

udy to assess the safety and tolerability of intranasally delivered ALN-RSV01 versus placebo, administered to healthy adult volunteers experimentally inoculated with the RSV virus. The study, expected to enroll approximately 90 subjects, aims to determine the safety and anti-viral activity of ALN-RSV01 as measured toward clinical symptoms of RSV infection and RSV infection rate based on measures of viral load.

About Respiratory Syncytial Virus (RSV)

RSV is a highly contagious virus that causes infections in both the upper and lower respiratory tract. RSV infects nearly every child at least once by the age of two years and is a leading cause of hospitalization due to respiratory infection in children and in people with compromised immune systems, and others. RSV infection typically results in cold-like symptoms but can lead to more serious respiratory illnesses such as croup, pneumonia, bronchiolitis, and in extreme cases, death. RSV infection in the pediatric population accounts for more than 125,000 hospitalizations per year in the U.S. In addition, RSV infection in infants has been linked to the development of childhood asthma. As a result, there is a significant need for novel therapeutics to treat patients who become infected with RSV.

About RNA Interference (RNAi)

RNA interference (or RNAi) is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. The discovery of RNAi has been widely acknowledged as a major breakthrough in biology, and the technology was recognized for its potential broad impact in medicine with the award of the 2006 Nobel Prize for Physiology or Medicine. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi has accelerated the understanding of these genes and their related pathways. Additionally, RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Confirms Effectiveness of Autologous Therapy, DUSSELDORF, ... a two-year,representative study of knee osteoarthritis, published ... confirm,the safety and effectiveness of Orthokine therapy, ... own blood are,injected into the arthritic joint., ...
... Phase III Study to Explore the Effects of ... Calcitonin on Vertebral Fractures in Postmenopausal Women, ... (Nasdaq: EMIS ) announced today that Novartis ... III study exploring the,safety and efficacy of Salmon ...
Cached Medicine Technology:Orthokine Treatment is Effective for Knee Arthritis, Even After Two Years 2Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment 2
(Date:4/18/2014)... release is available in French . ... revolutionize surgical practice and regenerative medicine. A team led ... Chimie (CNRS/ESPCI Paris Tech) and Didier Letourneur from the ... 13), has just demonstrated that the principle of adhesion ... vivo to repair soft-tissue organs and tissues. This easy-to-use ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2
... Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced ... Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) as,its ... announced transaction,between Takeda Pharmaceutical Company Limited and Alnylam. ... of future milestone and royalty,payments. This transaction further ...
... of almonds closer to that of roses or bananas? Weizmann ... for the first time that smells can be mapped and ... appeared recently in Nature Methods, may help scientists to unravel ... as potentially enabling odors to be digitized and transferred via ...
... Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) (,Lotus, or the ... China ("PRC"), today,announced that it will conduct a ... May 27, 2008 to discuss the first quarter ... and Chief Executive Officer of Lotus,Pharmaceuticals, will be ...
... ON, May 27 /PRNewswire-FirstCall/ - AlphaRx (OTC ... proprietary drug,delivery technology to develop novel formulations ... and USAMRIID (U.S. Army Medical Research Institute ... Research and,Development Agreement for Material Transfer (MTA). ...
... UCLA have identified a type of leukemia stem cell and ... blood stem cells to become cancerous. , The discovery may ... attacking the disease at its very root and killing the ... The study appears in the May 22, 2008 issue of ...
... Dozens of Videos from Doctors and Students at Seattle Children,s Hospital, Swedish ... ... Available,Videos Offer Insight and Advice on Topics Ranging from Pediatrics to Cancer ... Screening to Novel Surgical Techniques, NEW YORK, May 27 ...
Cached Medicine News:Health News:Isis to Receive $4.6 Million From Alnylam 2Health News:Isis to Receive $4.6 Million From Alnylam 3Health News:Weizmann Institute scientists produce the first smell map 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 3Health News:AlphaRx Signs Cooperative Research and Development Agreement with US Army 2Health News:UCLA researchers identify leukemia stem cells 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 3
... The aliquot! The aliquot from Genetix is ... with 96, 384, and 1536 well microplates. ... backfilling facility and optional microplate stacker, the ... low volume dispensing needs. The aliQuot's compact ...
... is a compact and self-contained multichannel ... a unique flow-through device, which allows ... wash system. Optional refill system ... Will be upgradable to with ...
... Aquarius 96 is a compact and self-contained ... fixed tip manifold can be used in ... washed in the optional active wash system. ... dust and adds safety. ...
... ideal system for fast, accurate filling of 96 ... valve controlled dispensing mechanism, ensures that no liquid ... components that come into contact with the liquid ... The unique compact design saves valuable bench space ...
Medicine Products: